Targeted improvement in heart failure
Targeting PARP16 alleviates pressure overload-induced pathological cardiac hypertrophy and fibrosis, offering a new target for effective heart failure therapy.
Su, Haibi · Xu, Jie · Su, Zhenghua · Xiao, Chenxi · Wang, Jinghuan · Zhong, Wen · Chen, Meng · Di, Yang · Zhu, Yizhun
Cellular and Molecular Life Sciences 2023
PARP16 deficiency rescues cardiac dysfunction and ameliorates TAC-induced cardiac hypertrophy and fibrosis in vivo
Overexpression of PARP16 exacerbates hypertrophic responses including augmented cardiomyocyte surface area and upregulation of fetal gene expressions
PARP16 interacts with IRE1α and ADP-ribosylates IRE1α, mediating hypertrophic responses via activating the IRE1α-sXBP1-GATA4 pathway